Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurotrope, Inc.NTRP · Entity 144906 | Director | December 01, 2020 | December 03, 2020 |
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | Director | June 05, 2026 | June 05, 2026 |
| Q/C TECHNOLOGIES, INC.QCLS · Entity 7735 | Director | April 13, 2026 | April 15, 2026 |
| RRE Ventures Acquisition Corp.RREV · Entity 5843 | Director | March 02, 2026 | May 05, 2026 |
| TAO Synergies Inc.TAOX · Entity 7482 | Director | May 18, 2026 | May 19, 2026 |
| WRAP TECHNOLOGIES, INC.WRAP · Entity 6770 | Director | October 01, 2026 | October 10, 2026 |
| XWELL, Inc.XWEL · Entity 1233 | Director | August 25, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurotrope, Inc.
Report date December 01, 2020 · Filed December 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 1
1 source rowRow 1 · 2020-12-01 · Disposition to issuer · Disposed 1,565 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-01 · Disposition to issuer · Disposed 7,813 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-12-01 · Disposition to issuer · Disposed 15,535 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-12-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97 | Direct | 0 |
Reported balance
After 2020-12-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-12-01 · Disposition to issuer · Disposed 72,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Petros Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,762,334 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 1,875,000 · Balance 3,762,334 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.
Q/C TECHNOLOGIES, INC.
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2036-04-13 | Direct | 50,000 |
Reported balance
After 2026-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer.
RRE Ventures Acquisition Corp.
Report date March 02, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 40,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 40,000 · Balance 40,000 F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: These securities were previously reported on a Form 3 filed by the Reporting Person. |
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 115,000 |
Reported balance
After 2026-03-25 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-25 · Grant · Acquired 75,000 · Balance 115,000 F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. F2: These securities were previously reported on a Form 3 filed by the Reporting Person. |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 250,000 |
Reported balance
After 2026-05-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-01 · Grant · Acquired 250,000 · Balance 250,000 F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
F2: These securities were previously reported on a Form 3 filed by the Reporting Person.
F3: The private placement warrants will become exercisable 30 days after the completion of the Issuer's initial business combination and will expire five years after the completion of the Issuer's initial business combination or earlier upon liquidation.
TAO Synergies Inc.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18 | Direct | 55,000 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 55,000 · Balance 55,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.
WRAP TECHNOLOGIES, INC.
Report date October 01, 2026 · Filed October 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,002 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 21,154 · Balance 272,002 F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"). On the date of grant, 13,750 of the RSUs vested and the remainder of the RSUs vest ratably in eight monthly tranches.
XWELL, Inc.
Report date August 25, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 839,882 |
Reported balance
After 2026-08-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-25 · Grant · Acquired 500,000 · Balance 839,882 F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted shares of the Issuer's common stock, par value $0.01 which vested fully on the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2017 Filed Aug 15, 2017 20:14 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 1,500 | $1.14 | $1,707.00 |
DisclosureSEC source: 0001144204-17-043501 · v473318_4.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,245 Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 20:14 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 1,500 | $1.15 | $1,725.00 |
DisclosureSEC source: 0001144204-17-043501 · v473318_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,745 Read SEC document |
| May 18, 2017 Filed May 19, 2017 14:07 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 20,000 | $1.64 | $32,700.00 |
DisclosureSEC source: 0001144204-17-028538 · v467438_form4.xml · nonDerivative · entry 3 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,245 Read SEC document |
| May 18, 2017 Filed May 19, 2017 14:07 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 1,200 | $1.45 | $1,740.00 |
DisclosureSEC source: 0001144204-17-028538 · v467438_form4.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,245 Read SEC document |
| May 18, 2017 Filed May 19, 2017 14:07 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 2,500 | $1.47 | $3,675.00 |
DisclosureSEC source: 0001144204-17-028538 · v467438_form4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,045 Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 21:51 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.10 | $0.00 |
DisclosureSEC source: 0001144204-17-015931 · v462245_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-17 F1 · security: Represents the annual option grant to each of the Issuer's non-employee directors on the fifth business day after the Issuer's filing of its Annual Report on Form 10-K pursuant to the Issuer's Nonemployee Director Compensation Policy. Such option grant is subject to stockholder approval of the Issuer's 2017 Equity Incentive Plan under which the option was granted. Read SEC document |
| January 20, 2017 Filed Jan 20, 2017 22:47 UTC | XWELL, Inc. FH · Entity 1233 | GrantCommon Stock | 84,243 | $2.31 | $194,601.33 |
DisclosureSEC source: 0001144204-17-003267 · v456887_form4.xml · nonDerivative · entry 3 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 377,545 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 8, 2016, among FORM Holdings Corp., FHXMS, LLC, XpresSpa Holdings LLC ("XpresSpa"), Mistral XH Representative, LLC, as Unitholders' Representative, and certain XpresSpa unitholders, as amended (the "Merger Agreement"), as of the date of this filing, 283,802 shares of Series D Convertible Preferred Stock have been deposited into various escrow accounts for a period of 18 months, or such other term related to specific escrows, to cover certain indemnification claims that may be made pursuant to the Merger Agreement. For the purposes of this filing, the Reporting Person has assumed that all shares held in escrow are released to the former holders of XpresSpa (and such shares, to the extent allocable to the Reporting Person pursuant to the Merger Agreement, have been included in his beneficial ownership for purposes of this filing). F2 · price: 258,712 shares of common stock were acquired in connection with the closing of the merger that was completed on December 23, 2016, which shares havebeen issued but not yet delivered. 84,243 shares of common stock were purchased in a private placement at a purchase price of $2.31 per share. F6 · ownership.nature: These securities are held by Rockmore Investment Master Fund Ltd., an investment entity controlled by Bruce T. Bernstein. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 22:47 UTC | XWELL, Inc. FH · Entity 1233 | GrantStock Option · Derivative | 85,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001144204-17-003267 · v456887_form4.xml · derivative · entry 6 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2027-01-17 F5 · price: These securities were issued as part of the Issuer's annual equity compensation to non-employee directors. F4 · derivative.exercise_date: These options to purchase shares of common stock of the Issuer vest in equal quarterly installments over a one-year period, with one-fourth vesting on the date of grant and one-fourth vesting at the end of each fiscal quarter thereafter Read SEC document |
| December 23, 2016 Filed Jan 20, 2017 22:47 UTC | XWELL, Inc. FH · Entity 1233 | GrantWarrant · Derivative | 258,712 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001144204-17-003267 · v456887_form4.xml · derivative · entry 5 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 276,074 Underlying: Common Stock · 258,712 shares Expires 2021-12-23 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 8, 2016, among FORM Holdings Corp., FHXMS, LLC, XpresSpa Holdings LLC ("XpresSpa"), Mistral XH Representative, LLC, as Unitholders' Representative, and certain XpresSpa unitholders, as amended (the "Merger Agreement"), as of the date of this filing, 283,802 shares of Series D Convertible Preferred Stock have been deposited into various escrow accounts for a period of 18 months, or such other term related to specific escrows, to cover certain indemnification claims that may be made pursuant to the Merger Agreement. For the purposes of this filing, the Reporting Person has assumed that all shares held in escrow are released to the former holders of XpresSpa (and such shares, to the extent allocable to the Reporting Person pursuant to the Merger Agreement, have been included in his beneficial ownership for purposes of this filing). F2 · price: 258,712 shares of common stock were acquired in connection with the closing of the merger that was completed on December 23, 2016, which shares havebeen issued but not yet delivered. 84,243 shares of common stock were purchased in a private placement at a purchase price of $2.31 per share. F6 · ownership.nature: These securities are held by Rockmore Investment Master Fund Ltd., an investment entity controlled by Bruce T. Bernstein. Read SEC document |
| December 23, 2016 Filed Jan 20, 2017 22:47 UTC | XWELL, Inc. FH · Entity 1233 | GrantSeries D Convertible Preferred Stock · Derivative | 51,203 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001144204-17-003267 · v456887_form4.xml · derivative · entry 4 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 54,640 Underlying: Common Stock · 409,624 shares Expires not disclosed F3 · shares: The Series D Convertible Preferred Stock matures seven years after the date of issuance and the Issuer will pay the holders in cash, shares of common stock, or any combination thereof. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 8, 2016, among FORM Holdings Corp., FHXMS, LLC, XpresSpa Holdings LLC ("XpresSpa"), Mistral XH Representative, LLC, as Unitholders' Representative, and certain XpresSpa unitholders, as amended (the "Merger Agreement"), as of the date of this filing, 283,802 shares of Series D Convertible Preferred Stock have been deposited into various escrow accounts for a period of 18 months, or such other term related to specific escrows, to cover certain indemnification claims that may be made pursuant to the Merger Agreement. For the purposes of this filing, the Reporting Person has assumed that all shares held in escrow are released to the former holders of XpresSpa (and such shares, to the extent allocable to the Reporting Person pursuant to the Merger Agreement, have been included in his beneficial ownership for purposes of this filing). F2 · price: 258,712 shares of common stock were acquired in connection with the closing of the merger that was completed on December 23, 2016, which shares havebeen issued but not yet delivered. 84,243 shares of common stock were purchased in a private placement at a purchase price of $2.31 per share. F3 · derivative.expiration_date: The Series D Convertible Preferred Stock matures seven years after the date of issuance and the Issuer will pay the holders in cash, shares of common stock, or any combination thereof. F6 · ownership.nature: These securities are held by Rockmore Investment Master Fund Ltd., an investment entity controlled by Bruce T. Bernstein. Read SEC document |
| December 23, 2016 Filed Jan 20, 2017 22:47 UTC | XWELL, Inc. FH · Entity 1233 | GrantCommon Stock | 258,712 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-003267 · v456887_form4.xml · nonDerivative · entry 2 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 293,302 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 8, 2016, among FORM Holdings Corp., FHXMS, LLC, XpresSpa Holdings LLC ("XpresSpa"), Mistral XH Representative, LLC, as Unitholders' Representative, and certain XpresSpa unitholders, as amended (the "Merger Agreement"), as of the date of this filing, 283,802 shares of Series D Convertible Preferred Stock have been deposited into various escrow accounts for a period of 18 months, or such other term related to specific escrows, to cover certain indemnification claims that may be made pursuant to the Merger Agreement. For the purposes of this filing, the Reporting Person has assumed that all shares held in escrow are released to the former holders of XpresSpa (and such shares, to the extent allocable to the Reporting Person pursuant to the Merger Agreement, have been included in his beneficial ownership for purposes of this filing). F2 · price: 258,712 shares of common stock were acquired in connection with the closing of the merger that was completed on December 23, 2016, which shares havebeen issued but not yet delivered. 84,243 shares of common stock were purchased in a private placement at a purchase price of $2.31 per share. F6 · ownership.nature: These securities are held by Rockmore Investment Master Fund Ltd., an investment entity controlled by Bruce T. Bernstein. Read SEC document |
| December 02, 2016 Filed Dec 2, 2016 13:49 UTC | Neurotrope, Inc. NTRP · Entity 144906 | PurchaseCommon Stock | 50,000 | $0.28 | $13,975.00 |
DisclosureSEC source: 0001144204-16-137638 · v454349_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 17:01 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option · Derivative | 497,096 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001144204-16-136404 · v453760_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,096 Underlying: Common Stock · 497,096 shares Expires 2026-11-21 F2 · price: These options were granted in connection with the Issuer's grant to certain officers, directors and employees following the final closing of a private placement on November 21, 2016. F1 · derivative.exercise_date: One half of the stock options vest immediately upon grant and the remaining one half vest in equal daily installments over a four-year period beginning on the date of grant. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 17:23 UTC | Neurotrope, Inc. NTRP · Entity 144906 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001144204-16-135433 · v453197_4.xml · derivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2026-11-16 F1 · shares: These securities were issued in connection with the Reporting Person's appointment as a non-employee director to the Issuer's board of directors. F2 · derivative.exercise_date: The stock options shall vest in equal daily installments over a five-year period beginning on the date of grant. Read SEC document |
| November 15, 2016 Filed Nov 18, 2016 01:51 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 1,960 | $2.35 | $4,606.00 |
DisclosureSEC source: 0001144204-16-135245 · v453420_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,090 Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 11:04 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 8,000 | $2.19 | $17,553.60 |
DisclosureSEC source: 0001144204-16-134547 · v453120_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,130 Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 12:45 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 11,430 | $2.10 | $24,001.86 |
DisclosureSEC source: 0001144204-16-124014 · v448852_4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,130 Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 12:46 UTC | XWELL, Inc. FH · Entity 1233 | PurchaseCommon Stock | 10,700 | $2.10 | $22,468.93 |
DisclosureSEC source: 0001144204-16-123812 · v448780_form4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,700 Read SEC document |
| December 03, 2015 Filed Jan 20, 2017 22:47 UTC | XWELL, Inc. FH · Entity 1233 | GrantCommon Stock | 2,500 | $3.16 | $7,900.00 |
DisclosureSEC source: 0001144204-17-003267 · v456887_form4.xml · nonDerivative · entry 1 Bernstein Bruce · CIK 0001665472 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.